Multiplex Assay Kit for Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) Rattus norvegicus (Rat) Multiplex ELISA

Endocan

(Note: Up to 8-plex in one testing reaction)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Multiplex Assay Kit for Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) Results demonstration
  • LMC463Ra.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 97-105 102
EDTA plasma(n=5) 79-101 94
heparin plasma(n=5) 79-99 92

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 89-97% 91-105% 89-98% 79-95%
EDTA plasma(n=5) 98-105% 79-98% 88-96% 84-98%
heparin plasma(n=5) 87-95% 79-96% 93-103% 89-97%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:ESM1) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Multiplex Assay Kit for Endothelial Cell Specific Molecule 1 (ESM1) ,etc. by FLIA (Flow Luminescence Immunoassay)

Test principle

Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.

Giveaways

Citations

  • Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantationPubMed: 22608803
  • Endocan is useful biomarker of survival and severity in sepsis.Pubmed: 24769132
  • Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromesPubmed:25211383
  • Endocan is useful biomarker of survival and severity in sepsisPubmed:24769132
  • Endocan Levels and Subclinical Atherosclerosis in Patients With Systemic Lupus ErythematosusPubMed: 26614790
  • Assessment of subclinical cardiac damage in chronic plaque psoriasis patients: a case control studyJournal:-102
  • Inhibition of endocan attenuates monocrotaline-induced connective tissue disease related pulmonary arterial hypertension.pubmed:27912147
  • Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancerpubmed:28514746
  • Changes in Endocan Levels and Blood Coagulation in HIV InfectionDOI: 10.13005/bpj/1082
  • A novel role of endocan in alleviating LPS-induced acute lung injuryPubmed:29627442
  • Is the plasma endocan level a reliable predictor for the severity of erectile dysfunction?Pubmed:30054863
  • Serum Level of Endothelial Cell-Specific Molecule-1 (ESM-1) as a New Potential Biomarker for Rheumatoid Arthritis Disease ActivityDoi: 10.2174/1874312901812010189
  • Downregulation of ENDOCAN in myeloid leukemia cells inhibits proliferation and promotes apoptosis by suppressing nuclear factor‑κB activityPubmed: 30816462
  • Endothelial biomarkers in the light of new sepsis definitionPubmed: 30920847
  • Risk stratification and prognostic evaluation of endothelial cell‑specific molecule1, von Willebrand factor, and a disintegrin‑like and metalloprotease with …
  • A novel marker relationship between carotid intima–media thickness and disease activity score-28 in patients with rheumatoid arthritis: human endothelial cell …Pubmed: 31655533
  • Role of Ascitic Endocan Levels in the Diagnosis of Spontaneous Bacterial Peritonitis in Decompensated CirrhosisPubmed: 32364003
  • Comparison of the maternal serum endocan levels in preterm premature rupture of membrane and normal pregnancy34109715
  • The relationship between serum endocan levels with the presence of contrast-induced nephropathy in patients undergoing coronary angiography

Recommend products